Transcriptomic Analyzes (RNA-Seq)
BioDecision Analytics offers intelligent solutions that allow transforming transcriptomic data from RNA sequencing (RNA-Seq) into information that helps in the interpretation of in vitro, preclinical, and/or clinical results. We also have an RNA-Seq analysis method developed to serve the pharmaceutical and biopharmaceutical industries. Through advanced bioinformatics analysis, our company counts on an exclusive service for the drug or biopharmaceuticals’ mechanism of action (MoA) prediction. By integrating the results of the transcriptomic analysis with in vitro, preclinical, and/or clinical data, through our application of Data Analytic techniques, we work to provide evidence of the mechanism of action supporting regulatory processes and adding economic value to investigational products.
How we do?
Developed in the mid-2000s, RNA sequencing (RNA-Seq) represents one of the greatest milestones in Life Science. This is because RNA-Seq allows to simultaneous assessment of the presence and quantity of gene products (also known as RNA or transcripts) in biological samples of interest. Through the combination of computational tools (bioinformatics) and appropriate statistical methods, the transcripts expressed by each biological sample (transcriptome) can be compared with the reference transcriptome of the studied specie or with the transcriptome of control samples (for experiments) or other samples from the same analyzed specie. Such analyzes allow identifying:
• Differentially expressed genes
• Mutations
• Gene fusions
• Transcripts that underwent alternative splicing
The RNA-Seq analysis workflow is summarized below: